Ripretinib, a switch‐control TKI, broadly inhibits wild‐type KIT/PDGFA mutations and multiple primary and secondary KIT/PDGFRA mutations associated with drug‐resistant GIST. The gene discussed is PDGFA; the disease is gastrointestinal stromal tumor.